New Choices for Central Venous Catheters: Potential Financial Implication

Shorr, Andrew F.; Humphreys, Christopher W.; Helman, Donald L.; Ramage, Anthony S.

doi:10.1378/chest.124.4_meetingabstracts.182s

Cited by 20 publications

(35 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In each of the studies, health outcomes were managed differently and a range of cost-effectiveness ratios was used: cost per infectious case, cost per quality-adjusted life-year (QALY) and cost per CRBSI avoided. As presented in 82 and Veenstra 31 studies, the CHSS and MR CVCs used were extraluminally coated; in the Shorr 83 study both the CHSS and MR CVCs were intraluminally and extraluminally coated. Although unstated, the date of publication suggests that the CHSS CVC used in the Frank 81 study is only coated on the external surface.…”

Section: Characteristics Of Economic Evaluationsmentioning

confidence: 99%

“…31,[81][82][83] Three of these four studies reported the results of full economic evaluations; one study 81 was published as a letter. Overall, the quality of the full economic evaluation papers was high.…”

Section: Quantity and Quality Of Research Availablementioning

confidence: 99%

“…From the data presented it was not possible to determine how Frank and colleagues 81 estimated the incremental costeffectiveness ratios (ICERs) quoted. Also, in the paper by Shorr and colleagues 83 there is confusion regarding the base-case incidence rate of CRBSIs.…”

Section: Quantity and Quality Of Research Availablementioning

confidence: 99%

“…The studies by Shorr 83 and Veenstra 31 used hypothetical cohorts of patients, while Frank 81 and Marciante 82 used efficacy data from patients who were participants in clinical trials. Marciante 82 looked at the costs and benefits of the new technologies over the lifetime of the patient, whereas the other papers appeared to focus on immediate costs and benefits.…”

Section: Characteristics Of Economic Evaluationsmentioning

confidence: 99%

“…However, randomised trial data were used to inform all of the studies. Shorr 83 uses original patient-level data from a large RCT, which compared CHSS CVCs with MR CVCs; Veenstra 31 and Marciante 82 both base their clinical effectiveness analysis on published trial data, including meta-analyses. Frank 81 uses data from a non-randomised clinical trial and meta-analysis of RCTs.…”

Section: Health Outcome Data and Data Sourcesmentioning

confidence: 99%

See 4 more Smart Citations

The clinical effectiveness and cost-effectiveness of central venous catheters treated with anti-infective agents in preventing bloodstream infections: a systematic review and economic evaluation

Hockenhull¹,

Dwan²,

Boland³

et al. 2008

Health Technol Assess

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) Programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, the public and consumer groups and professional bodies such as royal colleges and NHS trusts. These sugges...

show abstract

Section: Characteristics Of Economic Evaluationsmentioning

confidence: 99%

Section: Quantity and Quality Of Research Availablementioning

confidence: 99%

Section: Quantity and Quality Of Research Availablementioning

confidence: 99%

Section: Characteristics Of Economic Evaluationsmentioning

confidence: 99%

Section: Health Outcome Data and Data Sourcesmentioning

confidence: 99%

See 3 more Smart Citations

The clinical effectiveness and cost-effectiveness of central venous catheters treated with anti-infective agents in preventing bloodstream infections: a systematic review and economic evaluation

Hockenhull¹,

Dwan²,

Boland³

et al. 2008

Health Technol Assess

View full text Add to dashboard Cite

show abstract

Economic Evaluation of Quality Improvement Interventions for Bloodstream Infections Related to Central Catheters

et al. 2016

View full text Add to dashboard Cite

show abstract

Distinctin improves the efficacies of glycopeptides and betalactams against staphylococcal biofilm in an experimental model of central venous catheter infection

Giacometti

Cirioni

Ghiselli

et al. 2006

J Biomedical Materials Res

View full text Add to dashboard Cite

The ability of microorganisms to adhere to medical implants is a problem of high visibility and has been focused in numerous investigations. To assess the efficacy of distinctin and conventional antibiotics in the treatment of central venous catheter in vitro and in vivo studies were performed. The in vitro susceptibility assay was performed against S. aureus biofilms developed on 96-well polystyrene tissue culture plates. Efficacy studies were performed in a rat model of CVC infection. Twenty-four hours after implantation, the catheters were filled with distinctin. Thirty minutes later, rats were challenged via the CVC with S. aureus. Administration of antibiotics into the CVC at a concentration equal to the MBC for adherent cells, or at 1024 microg/mL began 24 h later. The killing activities of all antibiotics against adherent bacteria were at least four- to eightfold lower than against freely growing cells. When antibiotics were used in distinctin pretreated wells, they showed a significant increase of activity. The in vivo studies showed that when CVCs were pretreated with distinctin biofilm bacterial load was further decreased to 10(1) CFU/mL and bacteremia was not detected. Distinctin displays potential as an adjunctive agent to antibiotics in the treatment of CVC-related infections.

show abstract

New Choices for Central Venous Catheters: Potential Financial Implication

Cited by 20 publications

References 36 publications

The clinical effectiveness and cost-effectiveness of central venous catheters treated with anti-infective agents in preventing bloodstream infections: a systematic review and economic evaluation

The clinical effectiveness and cost-effectiveness of central venous catheters treated with anti-infective agents in preventing bloodstream infections: a systematic review and economic evaluation

Economic Evaluation of Quality Improvement Interventions for Bloodstream Infections Related to Central Catheters

Distinctin improves the efficacies of glycopeptides and betalactams against staphylococcal biofilm in an experimental model of central venous catheter infection

Contact Info

Product

Resources

About